Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preliminary Evaluation of 225Ac/177Lu-DOTATATE PRRT in Progressive Meningiomas: Efficacy, Dosimetry, and Imaging Insights.

Clinical nuclear medicine·2026

Same author

Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

Late post-treatment 131I SPECT/CT reveals additional lymph node metastasis of papillary thyroid carcinoma.

Nuklearmedizin. Nuclear medicine·2026

Same author

Multidisciplinary management of meningiomas in the era of precision oncology.

Nature reviews. Clinical oncology·2026

Same author

PET Molecular Imaging and Theranostics in Lung Diseases: Making Precision Medicine a Reality.

Chest·2026

Same author

Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: a systematic review and meta-analysis.

European journal of nuclear medicine and molecular imaging·2026

Search research articles

Related Experiment Video

Updated: May 30, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Targeted endoradiotherapy using nucleotides.

Agnieszka Morgenroth¹, Andreas T Vogg, Felix M Mottaghy

¹Department of Nuclear Medicine, University Hospital Aachen, RWTH, Pauwelsstraße 30, D-52074 Aachen, Germany. amorgenroth@ukaachen.de

Methods (San Diego, Calif.)

|July 26, 2011

Summary

This summary is machine-generated.

Nucleoside analogs that emit alpha and Auger electrons show promise for targeted cancer therapy by disrupting DNA replication. This review covers their development and studies, focusing on thymidine analogs for endoradiotherapy.

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Related Experiment Videos

Last Updated: May 30, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Area of Science:

Oncology
Radiotherapy
Molecular Biology

Background:

Cancer cells exhibit increased proliferation, requiring a constant supply of DNA building blocks.
This demand presents a therapeutic vulnerability that can be targeted for cancer treatment.

Purpose of the Study:

To review the development of nucleoside analogs for targeted endoradiotherapy.
To summarize preclinical and clinical studies of these analogs, with a focus on thymidine analogs.

Main Methods:

Review of scientific literature on nucleoside analogs.
Analysis of preclinical and clinical data for endoradiotherapeutic agents.
Focus on alpha and Auger electron emitting thymidine analogs.

Main Results:

Nucleoside analogs emitting alpha and Auger electrons are effective in targeting cancer cell DNA.
Preclinical and clinical studies demonstrate the potential of these analogs in endoradiotherapy.
Thymidine analogs are a key focus within this class of therapeutic agents.

Conclusions:

Targeting DNA replication with nucleoside analogs offers a promising strategy for cancer therapy.
Endoradiotherapy using alpha and Auger electron emitting nucleoside analogs, particularly thymidine analogs, warrants further investigation and development.